## Overview of Multiple Myeloma and Plasma Cell Neoplasms Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow. These cells are derived from the B-cell lineage and typically secrete a monoclonal (M) protein, which is an abnormal immunoglobulin or a fragment thereof (such as light chains). The category C90 encompasses several distinct yet related entities, including classic multiple myeloma, plasma cell leukemia, extramedullary plasmacytoma, and solitary plasmacytoma. ### Pathophysiology The pathogenesis of multiple myeloma involves a multi-step progression from a precursor state known as Monoclonal Gammopathy of Undetermined Significance (MGUS) to Smoldering Multiple Myeloma (SMM), and finally to symptomatic MM. This progression is driven by complex genetic alterations, including chromosomal translocations (e.g., involving the immunoglobulin heavy chain locus on chromosome 14) and numerical abnormalities (e.g., hyperdiploidy). The interaction between malignant plasma cells and the bone marrow microenvironment is critical; plasma cells stimulate osteoclasts while inhibiting osteoblasts via signaling pathways like RANK/RANKL and Dickkopf-1 (DKK1), leading to the characteristic lytic bone destruction. Furthermore, the production of excessive light chains can lead to renal damage through the formation of intratubular casts (cast nephropathy). ### Clinical Presentation and CRAB Criteria Patients often present with systemic manifestations summarized by the acronym **CRAB**: 1. **C**alcium elevation: Hypercalcemia due to increased bone resorption. 2. **R**enal insufficiency: Often characterized by an elevated serum creatinine resulting from light chain deposition. 3. **A**nemia: Normocytic, normochromic anemia due to marrow infiltration and cytokine-mediated suppression of erythropoiesis. 4. **B**one disease: Presence of one or more lytic lesions, severe osteopenia, or pathologic fractures. ### Diagnostic Criteria According to the International Myeloma Working Group (IMWG), the diagnosis of multiple myeloma requires the presence of clonal bone marrow plasma cells ≥10% or biopsy-proven extramedullary plasmacytoma, AND one or more myeloma-defining events (MDEs). MDEs include the CRAB features or any of the following biomarkers of malignancy: clonal bone marrow plasma cell percentage ≥60%, involved-to-uninvolved serum free light chain (FLC) ratio ≥100, or more than one focal lesion (≥5 mm each) on MRI. ### Management and Standard of Care Management depends on transplant eligibility, risk stratification, and patient comorbidities. For transplant-eligible patients, the standard of care usually involves triplet or quadruplet induction therapy (e.g., bortezomib, lenalidomide, and dexamethasone [VRd], sometimes with daratumumab) followed by high-dose chemotherapy with autologous stem cell transplantation (ASCT). Maintenance therapy, typically with lenalidomide, is used to prolong progression-free survival. Relapsed or refractory cases are treated with a variety of agents, including second-generation proteasome inhibitors (carfilzomib), immunomodulatory drugs (pomalidomide), monoclonal antibodies, and emerging therapies like CAR-T cell therapy or bispecific T-cell engagers (BiTEs).
Specify Clinical Status: Active, In Remission, or In Relapse
Example: Patient presents with IgG kappa multiple myeloma, currently in relapse (C90.02). Patient has completed second-line therapy with pomalidomide and is now exhibiting increasing M-protein levels and new onset bone pain. Current management involves initiating CAR-T cell therapy evaluation. Documentation supports HCC 12 risk adjustment by identifying the active relapsed state and high-intensity treatment plan.
Billing Focus: The 5th character (0, 1, or 2) is required to define the disease state (not in remission, in remission, in relapse) for proper code assignment.
Document Associated Complications (CRAB Criteria)
Example: Diagnosis: Multiple myeloma, not having achieved remission (C90.00), complicated by hypercalcemia (E83.52) and acute kidney injury (N17.9) secondary to light chain cast nephropathy. Patient is symptomatic with fatigue and thirst. Treatment includes aggressive hydration and pamidronate. Documentation of organ dysfunction links the malignancy to systemic severity for risk adjustment.
Billing Focus: Link complications specifically to the myeloma using 'due to' or 'secondary to' to capture the full clinical picture and justify higher-level E/M coding.
Distinguish from MGUS and Smoldering Myeloma
Example: Patient monitored for smoldering multiple myeloma (D47.Z9). Flow cytometry shows 15% plasma cells but patient remains asymptomatic with no lytic lesions or renal insufficiency. This is not coded as C90.00 at this stage. Documentation of 'smoldering' vs 'active' is critical for avoiding over-coding and audit risks.
Billing Focus: Ensure the diagnosis of C90 is only used when the patient meets IMWG diagnostic criteria for active malignancy, otherwise use D47.Z9 for uncertain behavior.
Identify Exact Malignant Cell Type
Example: Clinical assessment of plasma cell leukemia (C90.10) in a patient with absolute plasma cell count >2 G/L. This represents a more aggressive manifestation than standard multiple myeloma. Patient is currently not in remission and starting intensive induction. Accurate cell typing ensures specificity in ICD-10-CM.
Billing Focus: Specificity in cell type (e.g., extramedullary plasmacytoma C90.2x vs plasma cell leukemia C90.1x) changes the primary diagnosis code and potential DRG assignment.
Note Remission Type: Complete vs Partial
Example: Patient with multiple myeloma, now in complete remission (C90.01) following autologous stem cell transplant. No detectable M-spike on electrophoresis. Continuing maintenance therapy with lenalidomide. Specifying 'in remission' is required once the patient meets remission criteria even if maintenance drugs are continued.
Billing Focus: Coding C90.01 (in remission) is necessary once clinical criteria are met, even during maintenance therapy, to maintain longitudinal accuracy.
Standard for myeloma follow-up where treatment response is assessed and toxicities are managed.
Used for patients in relapse or with severe complications (renal failure, cord compression) requiring complex management changes.
Essential for confirming diagnosis, assessing plasma cell percentage, and cytogenetics.
Commonly used for monoclonal antibody infusions like daratumumab.
Used to assess bone loss related to myeloma and corticosteroid use.
The primary lab test for identifying the M-spike in myeloma.
Used (as UPEP) to detect Bence-Jones proteins in the urine.
Standard procedure for myeloma assessment.
Used to identify lytic lesions or occult fractures in the legs.
Used for administration of bortezomib (Velcade) or denosumab.